Wells Fargo & Company MN Has $634,000 Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Wells Fargo & Company MN lessened its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 83.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 74,208 shares of the biopharmaceutical company’s stock after selling 382,218 shares during the period. Wells Fargo & Company MN’s holdings in Ocular Therapeutix were worth $634,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. lifted its holdings in shares of Ocular Therapeutix by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 8,483,913 shares of the biopharmaceutical company’s stock worth $72,453,000 after buying an additional 99,730 shares during the last quarter. Deltec Asset Management LLC increased its position in Ocular Therapeutix by 0.6% during the fourth quarter. Deltec Asset Management LLC now owns 2,616,373 shares of the biopharmaceutical company’s stock worth $22,344,000 after acquiring an additional 16,300 shares during the period. Artisan Partners Limited Partnership raised its stake in Ocular Therapeutix by 26.4% during the 4th quarter. Artisan Partners Limited Partnership now owns 1,334,702 shares of the biopharmaceutical company’s stock valued at $11,398,000 after purchasing an additional 278,610 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Ocular Therapeutix by 1.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,131,485 shares of the biopharmaceutical company’s stock valued at $9,663,000 after purchasing an additional 21,025 shares during the period. Finally, Rosalind Advisors Inc. grew its position in Ocular Therapeutix by 27.5% in the 4th quarter. Rosalind Advisors Inc. now owns 1,128,700 shares of the biopharmaceutical company’s stock worth $9,639,000 after purchasing an additional 243,700 shares during the last quarter. Institutional investors own 59.21% of the company’s stock.

Insider Transactions at Ocular Therapeutix

In other Ocular Therapeutix news, insider Donald Notman sold 11,119 shares of the business’s stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $7.81, for a total transaction of $86,839.39. Following the sale, the insider now directly owns 193,444 shares of the company’s stock, valued at $1,510,797.64. The trade was a 5.44 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Pravin Dugel sold 21,475 shares of the stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $6.87, for a total transaction of $147,533.25. Following the transaction, the insider now owns 3,520,318 shares of the company’s stock, valued at approximately $24,184,584.66. This represents a 0.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.50% of the stock is owned by insiders.

Ocular Therapeutix Stock Performance

Shares of OCUL opened at $8.80 on Friday. The firm has a market cap of $1.40 billion, a P/E ratio of -6.67 and a beta of 1.49. Ocular Therapeutix, Inc. has a twelve month low of $4.79 and a twelve month high of $11.78. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.94 and a current ratio of 13.01. The firm’s 50 day moving average price is $7.40 and its two-hundred day moving average price is $8.43.

Ocular Therapeutix (NASDAQ:OCUL) last announced its earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.05). The company had revenue of $17.08 million during the quarter, compared to analyst estimates of $16.89 million. Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%. On average, analysts forecast that Ocular Therapeutix, Inc. will post -0.98 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on OCUL shares. William Blair assumed coverage on shares of Ocular Therapeutix in a research note on Tuesday, April 8th. They issued an “outperform” rating for the company. Royal Bank of Canada assumed coverage on Ocular Therapeutix in a research note on Tuesday, March 18th. They issued an “outperform” rating and a $17.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of Ocular Therapeutix in a report on Tuesday, March 4th. JMP Securities set a $19.00 price objective on Ocular Therapeutix in a report on Tuesday, March 4th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $15.00 price objective on shares of Ocular Therapeutix in a research report on Tuesday, April 8th. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, Ocular Therapeutix has a consensus rating of “Moderate Buy” and a consensus target price of $16.38.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.